Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Succinic lipoic amantadine tablets QT prolongation study
CTR20200956Phase 3Completed
- Sponsor
- Changchun Huayang High-tech Co., Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of succinic lipoic amantadine in Alzheimer's disease (AD), sponsored by Changchun Huayang High-tech Co., Ltd.. Started Jun 2020; status: completed.
02
Drugs
succinic lipoic amantadine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20200956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200956.